Praxis Precision Medicines Inc
PRAX
Company Profile
Business description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Contact
99 High Street
30th Floor
BostonMA02110
USAT: +1 617 300-8460
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
82
Stocks News & Analysis
stocks
Chart of the week: Why small caps could shine bright in 2025
The Chart of the Week is a reason why small caps may shine bright in 2025.
stocks
Dividend drought continues at ASX miner
Reduced payout rate and lower dividend but we leave our fair value unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,601.70 | 97.40 | -1.12% |
| CAC 40 | 8,122.58 | 12.04 | 0.15% |
| DAX 40 | 22,314.65 | 118.98 | -0.53% |
| Dow JONES (US) | 44,139.77 | 487.82 | -1.09% |
| FTSE 100 | 8,662.97 | 49.56 | -0.57% |
| HKSE | 22,576.98 | 367.26 | -1.60% |
| NASDAQ | 19,938.12 | 118.14 | -0.59% |
| Nikkei 225 | 38,678.04 | 486.57 | -1.24% |
| NZX 50 Index | 12,880.36 | 153.00 | -1.17% |
| S&P 500 | 6,113.00 | 31.15 | -0.51% |
| S&P/ASX 200 | 8,322.80 | 96.40 | -1.15% |
| SSE Composite Index | 3,350.78 | 0.76 | -0.02% |